AMG 337

DRUG5 trials

Sponsors

Amgen, NantPharma, LLC

Conditions

Advanced MalignancyAdvanced Solid TumorsCancerClear Cell SarcomaOncologyOncology PatientsSolid TumorStomach Neoplasms

Phase 1

A Study of AMG 337 in Subjects With Advanced Solid Tumors

CompletedNCT01253707

AmgenAdvanced Malignancy, Advanced Solid Tumors, Cancer +3

Start: 2010-12-08End: 2016-12-13Updated: 2022-11-07

A Phase 1/2 Study Evaluating AMG 337 in Asian Subjects

CompletedNCT02096666

AmgenStomach Neoplasms

Start: 2014-04-15End: 2018-12-07Updated: 2021-12-28

Phase 2

Phase 2 Study of AMG 337 in MET Amplified Gastric/Esophageal Adenocarcinoma or Other Solid Tumors

TerminatedNCT02016534

AmgenStomach Neoplasms

Start: 2014-02-28End: 2016-10-31Updated: 2017-07-02

QUILT-3.031: AMG 337 in Subjects With Advanced or Metastatic Clear Cell Sarcoma

TerminatedNCT03132155

NantPharma, LLCClear Cell Sarcoma

Start: 2018-08-29End: 2021-09-21Updated: 2024-05-24

QUILT-3.036: AMG 337 in Subjects With Advanced or Metastatic Solid Tumors

WithdrawnNCT03147976

NantPharma, LLCSolid Tumor

Start: 2018-05-02End: 2019-08-23Updated: 2019-08-28

Related Papers

A phase 1, open-label, dose escalation study of AMG 337 in Asian patients (pts) with advanced solid tumors.

Journal of Clinical Oncology2015-05-20

Clinical activity of AMG 337, an oral MET kinase inhibitor, in adult patients (pts) with MET-amplified gastroesophageal junction (GEJ), gastric (G), or esophageal (E) cancer.

Journal of Clinical Oncology2015-01-20109 citations

First-in-human study of AMG 337, a highly selective oral inhibitor of MET, in adult patients (pts) with advanced solid tumors.

Journal of Clinical Oncology2014-05-2027 citations